Inhalable nanocatalytic therapeutics for viral pneumonia
Source abstract
Abstract
Pneumonia is a ubiquitous disease caused by viral and bacterial infections, characterized by high levels of reactive oxygen species in inflamed areas. Therapeutic strategies targeting reactive oxygen species levels in pneumonia have limited success due to the intricate nature of lung tissues and lung inflammatory responses. Here we describe an inhalable, non-invasive therapeutic platform composed of engineered cerium-based tannic acid nanozymes bound to a self-assembling peptide. In vitro and in vivo studies show that the nanozyme is internalized mostly by activated macrophages and epithelial cells in the inflamed sites. In the oxidative environments of a mouse model of viral pneumonia, nanozyme aggregates into catalytically active structures that reduce reactive oxygen species levels and inflammatory cytokine production and promote macrophage polarization to the prohealing (M2) phenotype. Moreover, the nanozyme attenuates bacterial inflammation and reduces tissue damage in a mouse viral pneumonia model with secondary bacterial infection. Overall, this nanozyme platform is a promising strategy for treating pneumonia and its associated conditions.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Advanced biosensing and bioanalysis techniques · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Ruuskanen, O., Lahti, E., Jennings, L. C. & Murdoch, D. R. Viral pneumonia. Lancet 377, 1264–1275 (2011).10.1016/S0140-6736(10)61459-6 ↗
2. Wang, C. C. et al. Airborne transmission of respiratory viruses. Science 373, abd9149 (2021).10.1126/science.abd9149 ↗
3. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).10.1038/s41586-020-2012-7 ↗
4. Lessler, J. et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect. Dis. 9, 291–300 (2009).10.1016/S1473-3099(09)70069-6 ↗
5. Imai, Y. et al. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235–249 (2008).10.1016/j.cell.2008.02.043 ↗
6. Iwasaki, A. & Pillai, P. S. Innate immunity to influenza virus infection. Nat. Rev. Immunol. 14, 315–328 (2014).10.1038/nri3665 ↗
7. To, E. E. et al. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. Nat. Commun. 8, 69 (2017).10.1038/s41467-017-00057-x ↗
8. Noreng, S. et al. Structure of the core human NADPH oxidase NOX2. Nat. Commun. 13, 6079 (2022).10.1038/s41467-022-33711-0 ↗
9. Kim, S. Y. et al. Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4–MD2 complex. Nat. Commun. 8, 2247 (2017).10.1038/s41467-017-02325-2 ↗
10. Wallace, D. C. Mitochondrial diseases in man and mouse. Science 283, 1482–1488 (1999).10.1126/science.283.5407.1482 ↗
11. Dickinson, B. C. & Chang, C. J. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat. Chem. Biol. 7, 504–511 (2011).10.1038/nchembio.607 ↗
12. Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).10.1016/S0140-6736(20)31022-9 ↗
13. Hung, I. F. et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695–1704 (2020).10.1016/S0140-6736(20)31042-4 ↗
14. Gubareva, L. V., Kaiser, L. & Hayden, F. G. Influenza virus neuraminidase inhibitors. Lancet 355, 827–835 (2000).10.1016/S0140-6736(99)11433-8 ↗
15. Choudhary, M. C. et al. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat. Microbiol. 7, 1906–1917 (2022).10.1038/s41564-022-01254-1 ↗
16. Gillin, J. C., Jacobs, L. S., Fram, D. H. & Snyder, F. Acute effect of a glucocorticoid on normal human sleep. Nature 237, 398–399 (1972).10.1038/237398a0 ↗
17. Perretti, M. et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296–1302 (2002).10.1038/nm786 ↗
18. Snelgrove, R. J. et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 9, 1074–1083 (2008).10.1038/ni.1637 ↗
19. Crotty, S. et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6, 1375–1379 (2000).10.1038/82191 ↗
20. Driouich, J.-S. et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat. Commun. 12, 1735 (2021).10.1038/s41467-021-21992-w ↗
21. Shannon, A. et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 11, 4682 (2020).10.1038/s41467-020-18463-z ↗
22. Gao, L. et al. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. Nat. Nanotechnol. 2, 577–583 (2007).10.1038/nnano.2007.260 ↗
23. Richter, D. Decomposition of hydrogen peroxide by catalase. Nature 129, 870 (1932).10.1038/129870c0 ↗
24. Sies, H. Strategies of antioxidant defense. Eur. J. Biochem. 215, 213–219 (1993).10.1111/j.1432-1033.1993.tb18025.x ↗
25. Liu, B., Sun, Z., Huang, P. J. & Liu, J. Hydrogen peroxide displacing DNA from nanoceria: mechanism and detection of glucose in serum. J. Am. Chem. Soc. 137, 1290–1295 (2015).10.1021/ja511444e ↗
26. Allawadhi, P. et al. Nanoceria as a possible agent for the management of COVID-19. Nano Today 35, 100982 (2020).10.1016/j.nantod.2020.100982 ↗
27. Fu, X. et al. Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis. Nat. Commun. 13, 6528 (2022).10.1038/s41467-022-34248-y ↗
28. Zhang, Y. et al. Nanozymes for nanohealthcare. Nat. Rev. Methods Prim. 4, 36 (2024).10.1038/s43586-024-00315-5 ↗
29. Ma, X. et al. Prussian blue nanozyme as a pyroptosis inhibitor alleviates neurodegeneration. Adv. Mater. 34, 2106723 (2022).10.1002/adma.202106723 ↗
30. Wang, Z. et al. A thrombin-activated peptide-templated nanozyme for remedying ischemic stroke via thrombolytic and neuroprotective actions. Adv. Mater. 36, 2210144 (2024).10.1002/adma.202210144 ↗
31. Yu, P. et al. Mimicking antioxidases and hyaluronan synthase: a zwitterionic nanozyme for photothermal therapy of osteoarthritis. Adv. Mater. 35, 2303299 (2023).10.1002/adma.202303299 ↗
32. Wang, H. et al. Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. Nat. Biomed. Eng. 6, 882–897 (2022).10.1038/s41551-021-00815-9 ↗
33. Deng, C. et al. Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis. Nat. Commun. 12, 2174 (2021).10.1038/s41467-021-22454-z ↗
34. Huang, Y. et al. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduct. Target. Ther. 9, 34 (2024).10.1038/s41392-024-01745-z ↗
35. Cui, L. et al. CeO2 nanoparticles induce pulmonary fibrosis via activating S1P pathway as revealed by metabolomics. Nano Today 45, 101559 (2022).10.1016/j.nantod.2022.101559 ↗
36. Pauluhn, J. Kinetic modeling of the retention and fate of inhaled cerium oxide nanoparticles in rats: the cumulative displacement volume of agglomerates determines the outcome. Regul. Toxicol. Pharm. 86, 319–331 (2017).10.1016/j.yrtph.2017.03.023 ↗
37. Gupta, M. K. et al. Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release. J. Am. Chem. Soc. 136, 14896–14902 (2014).10.1021/ja507626y ↗
38. Shim, M. S. & Xia, Y. A reactive oxygen species (ROS)-responsive polymer for safe, efficient, and targeted gene delivery in cancer cells. Angew. Chem. Int. Ed. 52, 6926–6929 (2013).10.1002/anie.201209633 ↗
39. Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).10.1038/nature12202 ↗
40. Porotto, M., Greengard, O., Poltoratskaia, N., Horga, M. A. & Moscona, A. Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant. J. Virol. 75, 7481–7488 (2001).10.1128/JVI.75.16.7481-7488.2001 ↗
41. Zuo, Y. et al. Neutrophil extracelluar traps in COVID-19. JCI Insight 5, e138999 (2020).
42. Chen, H. Y. et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 383, 714–721 (2014).10.1016/S0140-6736(14)60111-2 ↗
43. Myerson, J. W. et al. Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nat. Nanotechnol. 17, 86–97 (2022).10.1038/s41565-021-00997-y ↗
44. Zhang, Q. et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat. Nanotechnol. 13, 1182–1190 (2018).10.1038/s41565-018-0254-4 ↗
45. Guo, J. et al. Engineering multifunctional capsules through the assembly of metal–phenolic networks. Angew. Chem. Int. Ed. 53, 5546–5551 (2014).10.1002/anie.201311136 ↗
46. He, Q. et al. Safeguarding osteointegration in diabetic patients: a potent ‘chain armor’ coating for scavenging ROS and macrophage reprogramming in a microenvironment-responsive manner. Adv. Funct. Mater. 31, 2101611 (2021).10.1002/adfm.202101611 ↗
47. Cheng, D. B. et al. Endogenous reactive oxygen species-triggered morphology transformation for enhanced cooperative interaction with mitochondria. J. Am. Chem. Soc. 141, 7235–7239 (2019).10.1021/jacs.8b07727 ↗